| Overview |
| bs-11793R-Cy7 |
| ENSA/ARPP-19 Polyclonal Antibody, Cy7 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Horse, Rabbit |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human ENSA/ARPP-19 |
| 51-121/121 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm |
| Alpha endosulfine; ARPP 19e; Endosulfine alpha; ENSA_HUMAN. |
| Sulfonylureas are a class of drugs commonly used in the management of noninsulin-dependent diabetes mellitus. ENSA/ARPP-19, also known as ARPP-19e, is a 121 amino acid protein that localizes to the cytoplasm and belongs to the endosulfine family. ENSA/ARPP-19 is an endogenous regulator of the _-cell K(ATP) channels and reduces K(ATP) channel currents by inhibiting sulfonylurea from binding to the receptor thereby stimulating insulin secretion by pancreatic _ cells. It is suggested that ENSA/ARPP-19 expression is decreased in brains of both Alzheimer's disease (AD) and Down's syndrome patients. Widely expressed with high levels in skeletal muscle and brain and lower levels in pancreas, ENSA/ARPP-19 is phosphorylated by PKA and exists as eight alternatively spliced isoforms. ENSA/ARPP-19 is encoded by a gene located on human chromosome 1q21.3. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz